Factors associated with a worse first-line treatment PFS in univariate Cox regression analysis were male sex (HR 2.02), NEC histology (HR 3.31), high Ki-67 index > 55% (HR 2.94), ECOG performance status of 1 or worse (HR 2.70), and treatment with platin/etoposide (HR 2.98), while history of primary tumor resection (HR 0.42) and positive SSTR imaging (HR 0.21) were associated with better progression-free survival. The gene discussed is MKI67; the disease is neuroendocrine carcinoma.